|
|
|
|
|
|
|
|
|
|
OPT Congress 2026 convenes the leaders advancing oligonucleotide, mRNA, and peptide therapeutics from discovery through commercialization. Across four focused conferences, explore 60+ presentations covering AI-enabled design, next-generation delivery, scalable manufacturing, and emerging conjugate platforms. Join a high-level community driving real translational impact. Use code OPS26ARNA for $200 off registration.
Download the brochure to view the full agenda and secure your place March 18–19 in Boston or virtually.
|
|
|
|
|
|
|
|
By Anna Rose Welch, Advancing RNA
|
In episode 2 of mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist, Advancing RNA's ARW sits down with Sophia Lugo and Michelle Lynn Hall to learn their wish lists for RNA developments for 2026 and their take on an edited quote by Oscar Wilde: “The mRNA industry can survive everything but…?”
|
|
|
|
|
|
Which Advanced Modalities Are Built For Commercial Scale In 2026?
|
|
By Carl Schoellhammer, Ph.D., DeciBio
|
In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits. How will this emerging era change how we see these therapies?
|
|
|
|
The mRNA Supply Chain Revolution: Materials, Methods, And Momentum
|
|
By Life Science Connect Editorial Staff
|
mRNA innovation now hinges as much on manufacturing materials as on molecular design, with novel inputs shaping performance, cost, and scalability. As these less-mature materials move rapidly into production, strategic material selection and supplier alignment are becoming critical to manufacturing resilience and long-term success.
|
|
|
|
|
|
|
|
|
|
|
Join Advancing RNA Live Chief Anna Rose Welch on March 26 at 11am Eastern, for Advancements in gRNA Manufacturing & Quality, a hot topic discussion on the critical element in gene editing therapy- Guide RNA. Panelists will examine potential strategies for retrofitting current facilities or outfitting new facilities to bring API manufacturing in-house. They will also explore opportunities in facility design, process updates, technological advancements, raw material sourcing, and more. Register for free today.
|
|
|
|
|
|
|
|
|
|
|
|
Elevating mRNA Manufacturing Toward GMP-Readiness
|
|
White Paper | MilliporeSigma
|
The mRNA Technology Transfer Program empowers LMICs with scalable vaccine production. Adopt a partnership that drives innovation in mRNA and sets a global blueprint for equitable health access.
|
|
|
|
|
|
|
|
The Sleek Science Of IP-RP Oligonucleotide Analysis
|
|
Article | KNAUER
|
Master oligonucleotide separation by balancing hydrophobic and ionic interactions. Selecting the right cationic pairing agent optimizes retention and ensures compatibility with mass spectrometry workflows.
|
|
|
|
|
|
|
|
|
The London Biotech Show 2026 is Europe’s leading platform for the biotechnology industry, showcasing the full spectrum of red biotech including biopharmaceuticals, therapeutics, gene and cell therapy, regenerative medicine, diagnostics, precision medicine, vaccines, clinical trials, and biomanufacturing. The event brings together biotech companies, pharmaceutical leaders, lab suppliers, medtech innovators, investors, researchers, policymakers, and solution providers from across the globe to exchange knowledge, forge partnerships, and accelerate innovation.
|
|
|
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
